amoxicillin clavulanate
DrugDose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
NCT Number: NCT03247920
Randomized controlled open-label non-inferiority trial comparing complete intravenous antibiotic treatment with a short iv. course followed by oral antibiotics in neonates (0-28 days) with probable bacterial infection.
Primary outcome:
- Bacterial re-infection within 28 days after finishing of antibacterial therapy.
Secondary outcome(s):
* Pharmacokinetic profile of oral amoxicillin/clavulanic acid * Quality of life * Cost-effectiveness * Alterations in gut microbiome * Use of molecular techniques for better detection of bacterial pathogens
Looking for future studies?
Notify Me1 day–28 day
All sexes
Interventional
Phase 4
Meander Medical Center, Amersfoort, Netherlands
Neonates have a high antibiotic consumption because of their susceptibility for bacterial infections. Since the early diagnosis of bacterial infection in neonates is difficult, intravenous broad-spectrum antimicrobial therapy is usually started promptly after subtle symptoms. The majority of neonates become asymptomatic shortly after initiation; when infection is probable or proven by elevated inflammatory markers and/or a positive blood culture, intravenous antibiotics are administered for at least 7 days.
However, for neonates blood culture has a limited sensitivity. Therefore, the majority of neonates with probable infection are treated for a prolonged time with intravenous broad-spectrum antimicrobial therapy. In older children, intravenous antibiotics are often changed to oral antibiotics after cessation of symptoms and decreasing inflammatory parameters. This is not yet widely practised in neonates because of uncertainties in pharmacokinetics. Two explorative small studies from France and Italy into neonatal antibiotic switch therapy suggest that follow-up treatment with an oral antibiotic is promising; but the non-inferiority and safety was not yet properly addressed. Neonatal switch therapy, if proven to be safe and efficacious, would have a major impact on neonatal well-being, mother-to-child bonding and moreover costs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
Intravenous antibiotic therapy following local protocol
Time frame: 0-35 days
Time frame: 0-35 days after birth
Time frame: 0-35 days after birth
Time frame: 0-35 days after birth
Cost-effectiveness of intravenous to oral switch compared to a full course of antibiotics + possible extra costs due to early antibiotic switch
Time frame: 0-35 days after birth
Two questionnaires on day 7 and 21 after admission, filled in by both parents. Data will be provided in a descriptive manner as no validated QoL questionnaires exist for neonates.
Time frame: 0-7 days
2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter.
Time frame: 0-7 days
2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T>MIC) will be defined. Target MIC is 8 mg/liter.
Franciscus Gasthuis
Other
Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness
Acronym: RAIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05226949
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections
Copenhagen, Denmark
View Trial DetailsNCT02486783
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Paramaribo, Suriname
View Trial DetailsNCT06592586
Bacterial Infections, Bacterial Infections and Mycoses
Copenhagen, Capital Region, Denmark
View Trial DetailsNCT04893343
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Filderstadt, Baden-Wurttemberg, Germany
View Trial Details